More on Athersys drug failure

|By:, SA News Editor

Shares of cell therapy firm Athersys (ATHX -56.4%) nosedive after its MultiStem treatment for ulcerative colitis (UC) fails to show a meaningful benefit after eight weeks following a single administration in UC patients who have not responded to other therapies in a Phase 2 clinical trial.

The primary efficacy endpoints were a change in endoscopic score from baseline as measured by modified Baron score at eight weeks and the change in Mayo rectal bleeding subscore from baseline at four and eight weeks.

At four weeks, the proportion patients responding to the therapy was much greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients.

16-week data, including the impact of second round dosing for a subset of patients, is still being evaluated.